Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinomaMakoto Chuma, Shin Maeda, Hidenori Toyoda et al.|Hepatology International|2024Cited by 11